Medically refractory neurosarcoidosis treated with infliximab
Article first published online: 20 APR 2011
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians
Internal Medicine Journal
Volume 41, Issue 4, pages 354–357, April 2011
How to Cite
Pereira, J., Anderson, N. E., McAuley, D., Bergin, P., Kilfoyle, D. and Fink, J. (2011), Medically refractory neurosarcoidosis treated with infliximab. Internal Medicine Journal, 41: 354–357. doi: 10.1111/j.1445-5994.2011.02457.x
Conflict of interest: None.
- Issue published online: 20 APR 2011
- Article first published online: 20 APR 2011
- Received 29 October 2009; accepted 21 January 2010.
- monoclonal antibody;
- tumour necrosis;
- anti-inflammatory agent
Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a clinical response to this treatment and side effects were limited. A summary of reported cases of neurosarcoidosis treated with infliximab is included. This case series supports a role for infliximab in the treatment of patients with medically refractory neurosarcoidosis.